Exhibit 10.1  
 SECURITIES PURCHASE AGREEMENT  
 This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, among Leap Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser whose name is set forth on Exhibit A (each a “Purchaser” and collectively the “Purchasers”).  
 WHEREAS, the Company and the undersigned Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”); and  
 WHEREAS, on the terms and subject to the conditions set forth in this Agreement, the Company desires to sell and issue to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), and/or a pre-funded warrant to purchase shares of Common Stock in the form attached hereto as Exhibit B (each a “Pre-Funded Warrant”).  
 Now, Therefore, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser, severally and not jointly, agree as follows:  
 1. DEFINITIONS  
 1.1 Definitions. The following terms have the meanings set forth in this Section 1.1 or elsewhere in this Agreement as provided below in this Section 1.1:  
 “Board of Directors” means the board of directors of the Company.